Terry Geurkink, MD in Belleville, WI - Emergency Medicine

Terry Geurkink, MD is a Emergency Medicine physician based in Belleville, Wisconsin. Terry Geurkink is licensed to practice in Wisconsin (license number 22973) and his current practice location is 1675 Bartlett Ct, Belleville, Wisconsin. He can be reached at his office (for appointments etc.) via phone at (608) 845-8458.

NPI number for Terry Geurkink is 1609858117 and his current mailing address is 1675 Bartlett Ct, Belleville, Wisconsin. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1609858117.

Contact Information

	Terry Geurkink, MD
	1675 Bartlett Ct, Belleville, WI 53508-9712
	(608) 845-8458
	Not Available

Physician's Profile

Full Name	Terry Geurkink
Gender	Male
Speciality	Emergency Medicine
Location	1675 Bartlett Ct, Belleville, Wisconsin
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1609858117
Provider Enumeration Date: 11/18/2005
Last Update Date: 02/23/2009

Medical Identifiers

Medical identifiers for Terry Geurkink such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1609858117	NPI	-	NPPES
30571400	Medicaid	WI

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207P00000X	Emergency Medicine	22973 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Terry Geurkink is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Terry Geurkink, MD 1675 Bartlett Ct, Belleville, WI 53508-9712 Ph: () -	Terry Geurkink, MD 1675 Bartlett Ct, Belleville, WI 53508-9712 Ph: (608) 845-8458

News Archive

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders.

Health panel urges baby boomers be tested for hepatitis C

An influential health advisory group has reversed itself and concluded that all baby boomers should be tested for hepatitis C, meaning that under the new health law many insurance plans will have to provide screening without charge to patients.

Fluxion Biosciences expands its IonFlux automated patch clamp system

Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.

Terry Geurkink, MD - Emergency Medicine in Belleville, WI